These results highlight the need to better investigate the mechanisms of action, define the optimal timing of administration and identify predictive biomarkers
Different approaches are explored, showing good efficacy and mixed tolerability, but further studies are needed to assess their feasibility
In a phase I/II study, the combination treatment was tolerable in men who had progressed on one novel anti-androgen therapy
The availability and affordability of a broad range of prescription cancer medicines have been analysed
Results from two studies shows promise for combination immunotherapy in a population with a high unmet need for new treatments
Encouraging efficacy data with anti-PD1 antibody in combination or as monotherapy
In the post-COVID-19 era, there is a need to evaluate the quality, safety and effectiveness of telehealth to deliver cancer care says ESMO Keynote Lecturer Dr Deborah Schrag
Findings from the TROPiCS-02 trial show an overall survival benefit of sacituzumab govitecan in heavily pre-treated patients but raise questions about its optimal clinical implementation
An interim analysis of phase III data further supports the use of abemaciclib plus non-steroidal aromatase inhibitor in patients with HR+, HER2– advanced breast cancer
After impressive results were achieved in melanoma, there is now great interest in exploring the potential of dual LAG3/PD-1 inhibition in other tumour types
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.